Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Fineline Cube Dec 19, 2025
Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Fineline Cube Dec 19, 2025
Drug

China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021

Fineline Cube Sep 9, 2022

According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...

Medical Device Policy / Regulatory

National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products

Fineline Cube Sep 9, 2022

The national high-value medical consumables joint procurement office released a set of guiding opinions on...

Company Drug

China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study

Fineline Cube Sep 9, 2022

Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...

Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Company Deals Digital

Realcan Pharma and AWS Expand Partnership for Digital Transformation

Fineline Cube Sep 9, 2022

China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed...

Company Legal / IP

Salipro Biotech Secures Patent Protection for Membrane Protein Stabilization Tech

Fineline Cube Sep 9, 2022

Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug...

Company Drug

Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction

Fineline Cube Sep 8, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...

Company

China Pharma H1 2022 Financials: 40% of Firms Report Revenue and Profit Growth

Fineline Cube Sep 8, 2022

A total of 449 pharmaceutical and health-tech companies listed in China have released their H1...

Company Deals

Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy

Fineline Cube Sep 8, 2022

China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+...

Company Drug

Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer

Fineline Cube Sep 8, 2022

China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...

Policy / Regulatory

NHSA Reveals Drugs Passing Initial Review for NRDL Inclusion

Fineline Cube Sep 8, 2022

The National Healthcare Security Administration (NHSA) released a notification listing the drugs that have passed...

Company Drug

Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC

Fineline Cube Sep 8, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...

Company Deals

Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma

Fineline Cube Sep 8, 2022

China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of...

Company Deals

CStone Pharmaceuticals Partners with Rigen Biotech on Thyroid Cancer RET Gene Testing

Fineline Cube Sep 8, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has entered into a partnership with Shanghai Rigen Biotech to...

Company Deals

Biocytogen and FineImmune Partner on Innovative Cell Therapy Drug Development

Fineline Cube Sep 8, 2022

China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with...

Company Deals

CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech

Fineline Cube Sep 8, 2022

China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...

Company Deals

Kelun Pharmaceutical Receives USD 35 Million from Merck Sharp & Dohme Corp.

Fineline Cube Sep 8, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD...

Posts pagination

1 … 560 561 562 … 599

Recent updates

  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
  • Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo
  • Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
  • Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Others

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.